How Two Researchers Turned Eye-Tracking Science Into a Breakthrough for Autism Diagnosis and Assessment

Join Dr. Cheryl Tierney and Kirsten Yurich as they sit down with Dr. Ami Klin and Dr. Warren Jones, the pioneering researchers whose groundbreaking work in social visual engagement laid the foundation for the development of EarliPoint.

In this BehaviorLive webinar, Drs. Klin and Jones share their journey from early discoveries in eye-tracking research to the clinical translation of their science into a scalable tool for earlier autism diagnosis and treatment planning.

Through personal reflections, insights from decades of research, and lessons learned from launching EarliPoint into real-world practice, attendees will gain an inside look at how innovative science can move from lab to clinic to transform autism care. The discussion highlights how translational research can change the future of diagnosis, treatment, and outcomes for children with autism—making this an event not to be missed.

The webinar will be held on November 25, 2025, from 12:00 PM to 1:00 PM EST, and includes 1 BACB Learning CEU. Attendance is included free with a BehaviorLive subscription, and registrants will also have access to the recorded session on-demand for CEUs.

Learning Objectives

Participants will:

  • Describe the scientific discoveries that led to the development of EarliPoint and their significance for early autism diagnosis.
  • Identify the challenges and opportunities in translating research innovations into clinical practice.
  • Explain how objective measurement of social visual engagement can enhance both diagnostic accuracy and individualized treatment planning.

Register now to reserve your spot and explore how groundbreaking research in eye-tracking is advancing the future of autism diagnosis and assessment.

FAQs

What is this webinar about?

This session features Dr. Ami Klin and Dr. Warren Jones discussing how decades of research in social visual engagement led to the development of the EarliPoint System. They’ll explain how objective data from eye-tracking studies can be translated into meaningful clinical insights for developmental evaluation.

Who should attend this event?

The webinar is designed for clinicians, researchers, and professionals working in developmental assessment, early intervention, and behavioral health who are interested in the role of objective data in clinical decision-making.

Can I watch the webinar after the live event?

Yes. Anyone who registers in advance can access the full recording on-demand through BehaviorLive, including CEU credit options for eligible participants.

Latest News

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder